Amylyx Pharmaceuticals to Announce Topline Results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia on August 18, 2026
Go back to Amylyx Pharmaceuticals to Announce Topline Results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia on August 18, 2026| (NASDAQ: AMLX) | Delayed: 33.88 -0.22 (0.65%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $34.10 | 52 Week High | $ | |||
| Open | $33.49 | 52 Week Low | $ | |||
| Day High | $34.72 | P/E | N/A | |||
| Day Low | $33.10 | EPS | $ | |||
| Volume | 1,166,470 | |||||
